Cargando…
Correction: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279657/ https://www.ncbi.nlm.nih.gov/pubmed/32499296 http://dx.doi.org/10.1136/jitc-2019-000155corr1 |
Ejemplares similares
-
The Society for Immunotherapy in Cancer statement on best practices for
multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and
validation
por: Taube, Janis M, et al.
Publicado: (2020) -
Immunohistochemistry (IHC) staining of in-vitro cancer cell-generated tumoroids
por: Amereh, Meitham, et al.
Publicado: (2023) -
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
por: Tan, Wei Chang Colin, et al.
Publicado: (2020) -
Best Practices for Technical Reproducibility Assessment of Multiplex Immunofluorescence
por: Laberiano-Fernández, Caddie, et al.
Publicado: (2021) -
On clustering for cell-phenotyping in multiplex immunohistochemistry (mIHC) and multiplexed ion beam imaging (MIBI) data
por: Seal, Souvik, et al.
Publicado: (2022)